332 related articles for article (PubMed ID: 27494852)
1. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
[TBL] [Abstract][Full Text] [Related]
2. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
3. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
4. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
7. PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context.
Valentino T; Palmieri D; Vitiello M; Pierantoni GM; Fusco A; Fedele M
Cell Death Dis; 2013 Dec; 4(12):e963. PubMed ID: 24336083
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
9. POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.
Pero R; Palmieri D; Angrisano T; Valentino T; Federico A; Franco R; Lembo F; Klein-Szanto AJ; Del Vecchio L; Montanaro D; Keller S; Arra C; Papadopoulou V; Wagner SD; Croce CM; Fusco A; Chiariotti L; Fedele M
J Biol Chem; 2012 May; 287(22):18308-17. PubMed ID: 22493480
[TBL] [Abstract][Full Text] [Related]
10. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
11. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
12. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
[No Abstract] [Full Text] [Related]
13. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
14. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl.
Bai M; Skyrlas A; Agnantis NJ; Kamina S; Tsanou E; Grepi C; Galani V; Kanavaros P
Mod Pathol; 2004 Jul; 17(7):847-56. PubMed ID: 15073604
[TBL] [Abstract][Full Text] [Related]
16. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
[TBL] [Abstract][Full Text] [Related]
17. Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma.
Xie X; Sundram U; Natkunam Y; Kohler S; Hoppe RT; Kim YH; Cook JR; Hammel J; Swerdlow SH; Guitart J; Smith MD; Bosler D; Listinsky C; Lossos IS; Hsi ED
Mod Pathol; 2008 Jun; 21(6):653-9. PubMed ID: 18264083
[TBL] [Abstract][Full Text] [Related]
18. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
19. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
[TBL] [Abstract][Full Text] [Related]
20. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
